# Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

> **NCT00634634** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00634634
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-11
- **Primary completion:** 2019-04-20
- **Final completion:** 2023-04-28
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-11-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634634, "Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00634634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*